Glaukos Corporation

GKOSNYSEUSD
144.01 USD
1.86 (1.31%)AT CLOSE (11:59 AM EDT)
144.02
0.01 (0.00%)
POST MARKET (AS OF 08:10 PM EDT)
Post Market
AS OF 08:10 PM EDT
144.02
0.01 (0.00%)
🔴Market: CLOSED
Open?$142.27
High?$144.16
Low?$140.91
Prev. Close?$142.15
Volume?978.7K
Avg. Volume?746.5K
VWAP?$142.69
Rel. Volume?1.31x
Bid / Ask
Bid?$102.23 × 500
Ask?$144.01 × 100
Spread?$41.78
Midpoint?$123.12
Valuation & Ratios
Market Cap?8.5B
Shares Out?58.7M
Float?57.4M
Float %?98.8%
P/E Ratio?N/A
P/B Ratio?12.61
EPS?-$3.22
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Employees
1.1K
Market Cap
8.5B
Industry
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Listed
2015-06-25
Address
1 GLAUKOS WAY
ALISO VIEJO, CA 92656
Phone: 949-367-9600
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.43Strong
Quick Ratio?4.73Strong
Cash Ratio?1.17Strong
Debt/Equity?0.10Low
ValuationRICHLY VALUED
Score
50/100
P/E?
N/A
P/B?
12.61HIGH
P/S?
15.34HIGH
P/FCF?
N/A
EV/EBITDA?
-53.6CHEAP
EV/Sales?
15.27HIGH
Returns & Efficiency
ROE?
-28.2%WEAK
ROA?
-21.2%WEAK
Cash Flow & Enterprise
FCF?$-35088000
Enterprise Value?$8.4B
Fundamentals ratios updated end of day